Xin Kai

Xin Kai has over 17 years of work experience in the field of immunotherapy and antibody research. Xin began their career in 2004 as a Ph.D. graduate student at Shandong University. In 2008, they became a joint Ph.D. student at Massachusetts General Hospital Cancer Center, Harvard Medical School, where they examined druggable signaling pathways in CLL patients and analyzed Sialic acid-binding immunoglobulin-type lectins (SIGLECs) family members’ expression of human PBMCs. In 2011, they became a Postdoctoral Research Fellow at the same institution and established a high-throughput gene-editing platform for somatic mutation studies and drug screening using CRISPR-Cas9 techniques. Xin then moved to the Ragon Institute of MGH, MIT and Harvard in 2015 as a Postdoctoral Research Fellow where they investigated O-acetylation of sialic acid in different immune cell populations and its regulation mechanisms of novel signal pathways in B cell tolerance, T-B cell collaboration and germinal center reaction of autoimmune disease. In 2017, they joined Compass Therapeutics LLC as a Scientist and identified and validated the lead molecules of monoclonal and bispecific antibodies with a focus on immune-oncology and autoimmunity targets. In 2019, they joined Luye Boston R&D as an Investigator & Manager, Translational Research, Cell Therapy and Antibody Research. Xin is currently the Director of immunotherapy, Discovery Biology at Hopewell Therapeutics Inc.

Xin Kai received a Bachelor's degree in Biologic Engineering from Qilu University of Technology from 2000 to 2004. Xin then went on to receive a Doctor of Philosophy (PhD) in Molecular and Cellular Immunology from Shandong University from 2004 to 2010.